{
  "config_id": "MED003(ii)-SINGLE",
  "config_name": "Alirocumab: PCSK9 Inhibitor",
  "scoring_method": "therapeutic_adherence",
  "configuration_json": {
    "method": "therapeutic_adherence",
    "formula": "Average adherence across 1 therapeutic intervention(s)",
    "evaluation_pattern": "daily_multi_therapeutic",
    "schema": {
      "measurement_type": "therapeutic_adherence",
      "evaluation_period": "daily",
      "success_criteria": "adherence_percentage",
      "calculation_method": "multi_therapeutic_average",
      "therapeutics": [
        {
          "name": "Alirocumab",
          "type": "MED",
          "dose_min": 75.0,
          "dose_max": 150.0,
          "unit": "milligram",
          "unit_symbol": "mg",
          "rollup": "75-150 mg",
          "frequency": "every 2 weeks",
          "frequency_days": 14.0,
          "timing": "Any",
          "category": "PCSK9 Inhibitor",
          "operator": "<>"
        }
      ],
      "therapeutics_count": 1,
      "target_adherence": 90.0,
      "unit": "percent",
      "progress_direction": "maximize",
      "required_days": null,
      "total_days": 30,
      "description": "Adherence tracking for 1 therapeutic intervention(s): Alirocumab"
    }
  },
  "metadata": {
    "recommendation_text": "Take 75-150mg of Alirocumab at any time every 2 weeks for optimal cholesterol control and cardiovascular protection",
    "recommendation_id": "MED003(ii)-SINGLE",
    "analysis": {
      "algorithm_type": "therapeutic_adherence",
      "confidence": 1.0,
      "reasoning": "Multi-therapeutic adherence tracking for 1 intervention(s)"
    },
    "therapeutics_details": [
      {
        "name": "Alirocumab",
        "type": "MED",
        "dose_min": 75.0,
        "dose_max": 150.0,
        "unit": "milligram",
        "unit_symbol": "mg",
        "rollup": "75-150 mg",
        "frequency": "every 2 weeks",
        "frequency_days": 14.0,
        "timing": "Any",
        "category": "PCSK9 Inhibitor",
        "operator": "<>"
      }
    ],
    "generated_at": "2025-09-27T12:16:22.435704",
    "title": "Alirocumab: PCSK9 Inhibitor",
    "overview": "Monoclonal antibody for aggressive cholesterol control",
    "stack_summary": NaN,
    "stack_description": "",
    "option_count": "(ii)",
    "therapeutic_count": "SINGLE",
    "therapeutic_type": "MED",
    "age_range": "0-150",
    "gender": "male_female",
    "risk_level": "",
    "linked_evidence": NaN
  }
}